The EGFR mutation frequency was significantly higher in the TB group than in the non‐TB group (p < 0.05), and TB‐associated LC patients receiving EGFR‐TKIs treatment had poorer treatment response and survival rates (p < 0.05) [72]. Here, EGFR is linked to laryngotracheoesophageal cleft.